BackSino Biopharmaceutical Overview

Sino Biopharmaceutical Accounts Payable

Latest accounts payable for SBHMY: $2.2B.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$2.17B
↓ 23.20% YoYΔ $-654.27M vs prior year quarter

Peer trimmed avg / median

Loading

Sino Biopharmaceutical Accounts Payable History

Loading

Sino Biopharmaceutical vs. peers: Accounts Payable Comparison

Loading

Sino Biopharmaceutical Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sino Biopharmaceutical (SBHMY) FAQ

As of the most recent data (June 2026), SBHMY shows a accounts payable of $2.2B. That compares with $2.8B in the prior-year period — down 23.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBHMY's accounts payable is now $2.2B (was $2.8B) — a 23.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sino Biopharmaceutical is outperforming or lagging.

Tracking SBHMY's accounts payable over time shows whether Sino Biopharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $2.2B That compares with $2.8B in the prior-year period — down 23.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Sino Biopharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.2B) with ownership activity and broader fundamentals.

Sino Biopharmaceutical's accounts payable is $2.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.